Skip to content

Effect of Sil oil in Diabetes, hypertension and high Cholesterol levels.

A Prospective, Comparative, Open label Clinical Study to evaluate the Efficacy and Safety of Livvel Silk oil Soft gel Capsules in patients with Diabetes mellitus, Hypertension and Hyperlipidemia.

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/05/052246
Enrollment
100
Registered
2023-05-02
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E115- Type 2 diabetes mellitus with circulatory complications

Interventions

None listed

Sponsors

SEIDECOSAA Division of M/s INDIAN SILK FIBRE CO, India
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects, aged 18 years and above. Subjects diagnosed with Diabetes with hypertension and hyperlipidaemia, (newly diagnosed and patients who are on treatment).

Exclusion criteria

Exclusion criteria: 1. Subjects presenting with any other life threatening co morbid disease conditions like renal failure, liver failure or severe heart failure. 2. Participation in any other clinical study or test panel within the one month prior to entry into the study. 3. History of allergy to test product 4. History of HIV, HBV, Malignancy, alcohol or drug abuse. 5. Pregnant or lactating subjects.

Design outcomes

Primary

MeasureTime frame
â?¢Polyphagia, Polyurea, Polydipsia, Fatigue, weight loss and Blur vision (if any) â?¢Fasting blood glucose, Post prandial blood glucose and HbA1c levels â?¢Improvement of Systolic and Diastolic blood pressure â?¢Lowering of LDL/VLDL/TG and increase in HDL â?¢Number of Cardiovascular events (myocardial infarction/ stroke) during the study period. â?¢Improvement of Inflammatory markers like ESR and CRP. Timepoint: 4th 8th and 12th week

Secondary

MeasureTime frame
â?¢ Patient and investigator feedbacks and Quality of Life will be assessed â?¢ Adverse event monitoring (Laboratory data will be compared Pre and Post study to monitor for the safety of the subjects). Timepoint: 4th 8th and 12th week

Countries

India

Contacts

Public ContactDr Gayathri Sivakumar

kai3

saheerose@gmail.com9443627722

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026